Cox analysis of OS, DFS, relapse, and NRM
| Variable . | Effect . | OS . | DFS . | Relapse . | NRM . | ||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | P . | HR . | P . | HR . | P . | HR . | P . | ||
| HLA-DR mm GVH | Yes vs no | 0.43 | .001 | 0.47 | .002 | 0.51 | .023 | 0.39 | .031 |
| HLA-DP np mm | Yes vs no | 0.47 | .011 | 0.54 | .019 | 0.44 | .015 | 0.78 | .555 |
| CMV | D− R+ vs other | 1.57 | .043 | 1.51 | .049 | 1.34 | .259 | 1.83 | .083 |
| Patient age, y | ≥55 vs <55 | 1.92 | .002 | 1.76 | .005 | 1.62 | .052 | 2.04 | .040 |
| Race | Black vs White | 0.60 | .026 | 0.60 | .015 | 0.63 | .070 | 0.51 | .075 |
| DRI | High/very high vs low/intermediate | 2.17 | <.001 | 2.04 | <.001 | 2.39 | <.001 | 1.51 | .234 |
| Year of transplantation | 2011-2013 vs 2005-2010 | 0.97 | .901 | 0.90 | .700 | 0.60 | .118 | 2.02 | .147 |
| 2014-2016 vs 2005-2010 | 0.56 | .031 | 0.70 | .151 | 0.59 | .075 | 1.04 | .934 | |
| Variable . | Effect . | OS . | DFS . | Relapse . | NRM . | ||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | P . | HR . | P . | HR . | P . | HR . | P . | ||
| HLA-DR mm GVH | Yes vs no | 0.43 | .001 | 0.47 | .002 | 0.51 | .023 | 0.39 | .031 |
| HLA-DP np mm | Yes vs no | 0.47 | .011 | 0.54 | .019 | 0.44 | .015 | 0.78 | .555 |
| CMV | D− R+ vs other | 1.57 | .043 | 1.51 | .049 | 1.34 | .259 | 1.83 | .083 |
| Patient age, y | ≥55 vs <55 | 1.92 | .002 | 1.76 | .005 | 1.62 | .052 | 2.04 | .040 |
| Race | Black vs White | 0.60 | .026 | 0.60 | .015 | 0.63 | .070 | 0.51 | .075 |
| DRI | High/very high vs low/intermediate | 2.17 | <.001 | 2.04 | <.001 | 2.39 | <.001 | 1.51 | .234 |
| Year of transplantation | 2011-2013 vs 2005-2010 | 0.97 | .901 | 0.90 | .700 | 0.60 | .118 | 2.02 | .147 |
| 2014-2016 vs 2005-2010 | 0.56 | .031 | 0.70 | .151 | 0.59 | .075 | 1.04 | .934 | |
We considered the following variables in MVA: HLA-DR mm, HLA-DP np mm, age (<55 years vs ≥55 years), recipient sex, diagnosis (AML, ALL, or other), stem cell source (bone marrow vs PBSC), intensity (MA vs NMA), DRI (high/very high vs low/intermediate), HCT-specific comorbidity index (0-2 vs ≥3), donor age (<40 years vs ≥40 years), donor sex, CMV (D− R+ vs other), ABO compatibility (compatible, minor incompatible, or major incompatible), donor relationship (child, sibling, or parent), and year of transplantation (2005-2010, 2011-2013, or 2014-2016). The forward stepwise selection algorithm was implemented for each end point, and variables were selected by the 5% significance criterion. The final Cox models for OS, DFS, NRM, and relapse/progression were constructed by including all the variables significant for ≥1 end point.